| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966460 | Vaccine | 2014 | 7 Pages |
Abstract
Administration of two doses of MMRV has an acceptable safety profile in children 12 to 23 months of age. There is a small increase in the risk of febrile seizures following the first dose of MMRV as compared to the component vaccines, but the risk for any individual child is relatively low.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Stephanie O. Klopfer, Jon E. Stek, Maria Petrecz, Keith S. Reisinger, Steven B. Black, Michelle G. Goveia, Ouzama Nicholson, Julie L. Gardner, Anthony D. Grosso, Michelle L. Brown, Barbara J. Kuter, Florian P. Schödel,